Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotufolastat F-18 PET in prostate cancer with biochemical recurrence
NCT07115277Phase 3Recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fludeoxyglucose f 18 in prostate cancer (PCa), sponsored by Sinotau Pharmaceutical Group. Started Mar 2025; status: recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07115277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115277.